DL-Carnitine → (-)-Carnitine

반응식

[CH3:1][N+:2]([CH2:5][CH:6]([OH:11])[CH2:7][C:8]([O-:10])=[O:9])([CH3:4])[CH3:3].C([C@@](C(O)=O)(O)[C@@](C(=O)C1C=CC=CC=1)(O)C(O)=O)(=O)C1C=CC=CC=1>>[OH:11][C@@H:6]([CH2:7][C:8](=[O:9])[O-:10])[CH2:5][N+:2]([CH3:4])([CH3:1])[CH3:3].[OH:11][C@H:6]([CH2:7][C:8](=[O:9])[O-:10])[CH2:5][N+:2]([CH3:4])([CH3:1])[CH3:3]

참가 물질

반응물 2

HCID 288DL-Carnitine

HCID 12362976dibenzoyl-L(+)tartaric acid

생성물 2

HCID 10917(-)-Carnitine

HCID 2724480D-Carnitine

실험 절차

According to a preferred embodiment of the present invention, in the first step, to DL-carnitine is added dibenzoyl-L(+)tartaric acid and a lower alcohol, the mixture is dissolved under heat to form dibenzoyl-L(+)tartarates of D-carnitine and L-carnitine, and subsequently the tartarates are cooled to fractionally crystallize dibenzoyl-L(+)tartarate of L-carnitine.